Kelly Johnson

A mandate enacted after the 2010 Patient Protection and Affordable Care Act was supposed to improve health coverage for patients enrolled in clinical trials; however, nearly 63% of cancer centers and organizations that responded to a recent survey reported insurance denials of routine care costs associated with patient involvement in clinical trials during 2014.

Despite national evidence- and consensus- based guidelines on posttreatment care, fewer than half of adolescents and young adults with Hodgkin lymphoma receive all of the recommended services within the first year after treatment.

Manish A. Shah, MD, discusses the BRIGHTER trial, which is investigated BBI608 as a second-line treatment for patients with gastric and gastroesophageal junction cancer who already have undergone platinum and fluoropyrimidine-based chemotherapy.

Patients with a certain type of oral human papilloma virus have an increased risk of developing head and neck squamous cell carcinoma.

Philip J. Buffington, MD, discussed new screening methods and hormonal therapies being utilized for patients with metastatic prostate cancer.

Gary Kirsh, MD, president of The Urology Group and LUGPA, Kirsh provides insight on treating prostate cancer within the context of urology, as well as the benefits of a multidisciplinary approach.

Raoul S. Concepcion, MD, FACS, discussed novel therapies for treating mCRPC and deciding which patients are appropriate candidates.

ASCO and AAHPM recently partnered to create a consensus definition of high-quality palliative care.

Patients who have HPV 16 DNA in their saliva following treatment of their oropharyngeal cancer are more likely to have their cancer recur, and a prospective cohort study has shown that a simple mouth rinse can be used to detect it.